Precipio (NASDAQ:PRPO – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it contrast to its peers? We will compare Precipio to similar businesses based on the strength of its dividends, earnings, valuation, profitability, analyst recommendations, risk and institutional ownership.
Volatility & Risk
Precipio has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Precipio’s peers have a beta of 0.98, suggesting that their average share price is 2% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for Precipio and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| Precipio Competitors | 1880 | 7755 | 13395 | 833 | 2.55 |
Profitability
This table compares Precipio and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -4.12% | -7.84% | -5.37% |
| Precipio Competitors | -7.87% | -135.89% | -1.58% |
Institutional & Insider Ownership
10.4% of Precipio shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 16.6% of Precipio shares are owned by company insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Precipio and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Precipio | $27.76 million | -$360,000.00 | -34.69 |
| Precipio Competitors | $19.23 billion | $301.67 million | -1.64 |
Precipio’s peers have higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Precipio peers beat Precipio on 9 of the 13 factors compared.
Precipio Company Profile
Precipio is a diagnostics company focused on hematologic cancers and other complex diseases. It provides specialized pathology and laboratory testing services to help physicians identify and characterize blood disorders and malignancies. The company also develops and sells diagnostic products for use by clinical laboratories. Its HemeScreen platform offers molecular testing for genetic mutations associated with blood cancers, while its broader product offerings support laboratories seeking to perform specialized diagnostic tests.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
